 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults...

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients...

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) resubmission for TAK-721 (budesonide oral...

Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)

AvevoRx Signs Agreement for Subcutaneous Immunoglobulin Drug CUVITRU AvevoRx Signs Agreement for Subcutaneous Immunoglobulin Drug CUVITRU PR Newswire GREENSBORO, N.C., Sept. 14, 2023 Deal announced...

AvevoRx Signs Agreement for Subcutaneous Immunoglobulin Drug CUVITRU

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC...

Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohns Disease

Takeda (TSE:4502/NYSE:TAK) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and...

Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries

In trading on Tuesday, shares of Takeda Pharmaceutical Co Ltd (TAK) crossed above their 200 day moving average of 15.80, changing hands as high as 15.87 per share. Takeda Pharmaceutical Co...

TAK Makes Bullish Cross Above Critical Moving Average

Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral...

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical (NYSE:TAK  Get Free Report) had its target price lowered by JPMorgan Chase & Co. from $14.20 to $14.00 in a report released on Friday, FlyOnTheWall reports. JPMorgan...

Takeda Pharmaceutical (NYSE:TAK) PT Lowered to $14.00 at JPMorgan Chase & Co.

Gallacher Capital Management LLC lifted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK  Free Report) by 26.8% during the 1st quarter, according to the company in its...

Gallacher Capital Management LLC Has $231,000 Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Watchers	3,704
52-Wk Low	$12.28
52-Wk High	$17.15

Market Cap	$49.59B
Volume (M)	4,358.00
52-Wk High	$17.15
52-Wk Low	$12.28

TAK Takeda Pharmaceutical Co Ltd (ADR)

About

Feed

News

Sentiment

Fundamentals